# US 2020/0390850 A1 · Peptides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390850 A1
- Document ID: US20200390850A1
- Status: Published application
- Kind: A1
- Application number: 16/962,082
- Filed: 2019-01-15
- Published: 2020-12-17
- Earliest claimed: 2018-01-15
- Assignees: Lateral IP Pty Ltd
- Applicants: Lateral IP Pty Ltd
- Inventors: Andrew GEARING; David KENLEY
- Web page: https://patentgrep.com/patent/US20200390850A1

## CPC

- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/61: Growth hormone [GH], i.e. somatotropin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method of treating neuropathic pain in a subject, the method comprising administering to a subject a therapeutically effective amount of a peptide of formula (I) or (II), or a pharmaceutically acceptable salt thereof: R1-CRSVEG-SCG-R2 (I) (SEQ ID NO:1) wherein R1 is selected from the group consisting of YL-RIVQ, LRIVQ, RIVQ, IVQ, VQ, and Q, or R is absent; and R2 is F (phenylalanine) or R2 is absent. R1-CRRFVESSC-R2 (II) (SEQ ID NO:6) wherein R1 is selected from the group consisting of YLRVMIK, LRVMK, RVMK, VMK, MK, and K, or R1 is absent; and R2 is selected from the group consisting of A (alanie) and AF (alanine-phenylalanie), or R2 is absent.

## Claims

### Claim 1

A method of treating neuropathic pain in a subject, the method comprising administering to a subject a therapeutically effective amount of a peptide of formula (I), or a pharmaceutically acceptable salt thereof:
(I)
(SEQ ID NO: 1)
R1-CRSVEGSCG-R2
wherein
R1 is selected from the group consisting of YLRIVQ, LRIVQ, RIVQ, IVQ, VQ, and Q, or R1 is absent; and
R2 is F (phenylalanine) or R2 is absent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the peptide is selected from the group consisting of YLRIVQCRSVEGSCGF (SEQ ID NO:2), LRIVQCRSVEGSCGF (SEQ ID NO:3), CRSVEGSCG (SEQ ID NO:4) and CRSVEGSCGF (SEQ ID NO:5).

### Claim 3 (depends on 2)

The method of claim 2, wherein the peptide is YLRIVQCRSVEGSCGF (SEQ ID NO:2).

### Claim 4 (depends on 2)

The method of claim 2, wherein the peptide is CRSVEGSCG (SEQ ID NO:4).

### Claim 5 (depends on 2)

The method of claim 2, wherein the peptide is CRSVEGSCGF (SEQ ID NO:5).

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1 to 5, wherein said therapeutically effective amount alleviates neuropathic pain in the subject in the absence of a therapeutically effective analgesic effect on nociceptive pain.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1 to 6, wherein the subject is a human.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the neuropathic pain is selected from the group consisting of diabetic neuropathy; Herpes Zoster (shingles)-related neuropathy; fibromyalgia; multiple sclerosis, stroke, spinal cord injury; chronic post-surgical pain, phantom limb pain, Parkinson's disease; uremia-associated neuropathy; amyloidosis neuropathy; HIV sensory neuropathy; hereditary motor and sensory neuropathy (HMSN); hereditary sensory neuropathy (HSN); hereditary sensory and autonomic neuropathy; hereditary neuropathy with ulcero-mutilation; nitrofurantoin neuropathy; tomaculous neuropathy; neuropathy caused by nutritional deficiency, neuropathy caused by kidney failure, trigeminal neuropathic pain, atypical odontalgia (phantom tooth pain), burning mouth syndrome, complex regional pain syndrome, repetitive strain injury, drug-induced peripheral neuropathy and peripheral neuropathy associated with infection.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1 to 8, further comprising administering to the subject a therapeutically effective amount of a second agent capable of alleviating pain in the subject, wherein the second agent is not the peptide of formula (I) or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the second agent is capable of alleviating nociceptive pain in the subject.

### Claim 11

A pharmaceutical composition comprising a peptide of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of neuropathic pain in a subject:
(I)
(SEQ ID NO: 1)
R1-CRSVEGSCG-R2
wherein
R1 is selected from the group consisting of YLRIVQ, LRIVQ, RIVQ, IVQ, VQ, and Q, or R1 is absent; and
R2 is F (phenylalanine), or R2 is absent.

### Claim 12 (depends on 11)

The composition for use according to claim 11, wherein the peptide is selected from the group consisting of YLRIVQCRSVEGSCGF (SEQ ID NO:2), LRIVQCRSVEGSCGF (SEQ ID NO:3), CRSVEGSCG (SEQ ID NO:4) and CRSVEGSCGF (SEQ ID NO:5).

### Claim 13 (depends on 12)

The composition for use according to claim 12, wherein the peptide is YLRIVQCRSVEGSCGF (SEQ ID NO:2).

### Claim 14 (depends on 12)

The composition for use according to claim 12, wherein the peptide is CRSVEGSCG (SEQ ID NO:4).

### Claim 15 (depends on 12)

The composition for use according to claim 12, wherein the peptide is CRSVEGSCGF (SEQ ID NO:5).

### Claim 16 (depends on 11, 12, 13, 14, 15)

The composition for use according to any one of claims 11 to 15, wherein the peptide, or the pharmaceutically acceptable salt thereof, is present in a therapeutically effective amount that, when administered to a subject, alleviates neuropathic pain in the subject in the absence of a therapeutically effective analgesic effect on nociceptive pain.

### Claim 17 (depends on 11, 12, 13, 14, 15, 16)

The composition for use according to any one of claims 11 to 16, wherein the subject is a human.

### Claim 18 (depends on 11, 12, 13, 14, 15, 16, 17)

The composition for use according to any one of claims 11 to 17, wherein the neuropathic pain is selected from the group consisting of diabetic neuropathy: Herpes Zoster (shingles)-related neuropathy; fibromyalgia; multiple sclerosis, stroke, spinal cord injury; chronic post-surgical pain, phantom limb pain, Parkinson's disease; uremia-associated neuropathy; amyloidosis neuropathy; HIV sensory neuropathy; hereditary motor and sensory neuropathy (HMSN); hereditary sensory neuropathy (HSN); hereditary sensory and autonomic neuropathy; hereditary neuropathy with ulcero-mutilation; nitrofurantoin neuropathy; tomaculous neuropathy; neuropathy caused by nutritional deficiency, neuropathy caused by kidney failure, trigeminal neuropathic pain, atypical odontalgia (phantom tooth pain), burning mouth syndrome, complex regional pain syndrome, repetitive strain injury, drug-induced peripheral neuropathy and peripheral neuropathy associated with infection.

### Claim 19 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18)

The composition for use according to any one of claims 10 to 18, further comprising a second agent capable of alleviating pain in the subject, wherein the second agent is not the peptide of formula (I) or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 19)

The composition for use according to claim 19, wherein the second agent is capable of alleviating nociceptive pain in the subject.

### Claim 21

Use of a peptide of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of neuropathic pain in a subject:
(I)
(SEQ ID NO: 1)
R1-CRSVEGSCG-R2
wherein
R1 is selected from the group consisting of YLRIVQ, LRIVQ, RIVQ, IVQ, VQ, and Q, or R1 is absent; and
R2 is F (phenylalanine), or R2 is absent.

### Claim 22 (depends on 21)

Use of claim 21, wherein the peptide is selected from the group consisting of YLRIVQCRSVEGSCGF (SEQ ID NO:2), LRIVQCRSVEGSCGF (SEQ ID NO:3), CRSVEGSCG (SEQ ID NO:4) and CRSVEGSCGF (SEQ ID NO:5).

### Claim 23 (depends on 22)

Use of claim 22, wherein the peptide is YLRIVQCRSVEGSCGF (SEQ ID NO:2).

### Claim 24 (depends on 22)

Use of claim 22, wherein the peptide is CRSVEGSCG (SEQ ID NO:4).

### Claim 25 (depends on 22)

Use of claim 22, wherein the peptide is CRSVEGSCGF (SEQ ID NO:5).

### Claim 26 (depends on 21, 22, 23, 24, 25)

Use of any one of claims 21 to 25, wherein the peptide, or the pharmaceutically acceptable salt thereof, is formulated for administration to the subject in a therapeutically effective amount that alleviates neuropathic pain in the subject in the absence of a therapeutically effective analgesic effect on nociceptive pain.

### Claim 27 (depends on 21, 22, 23, 24, 25, 26)

Use of any one of claims 21 to 26, wherein the subject is a human.

### Claim 28 (depends on 21, 22, 23, 24, 25, 26, 27)

Use of any one of claims 21 to 27, wherein the neuropathic pain is selected from the group consisting of diabetic neuropathy; Herpes Zoster (shingles)-related neuropathy; fibromyalgia; multiple sclerosis, stroke, spinal cord injury; chronic post-surgical pain, phantom limb pain, Parkinson's disease; uremia-associated neuropathy; amyloidosis neuropathy; HIV sensory neuropathy; hereditary motor and sensory neuropathy (HMSN); hereditary sensory neuropathy (HSN); hereditary sensory and autonomic neuropathy; hereditary neuropathy with ulcero-mutilation; nitrofurantoin neuropathy; tomaculous neuropathy; neuropathy caused by nutritional deficiency, neuropathy caused by kidney failure, trigeminal neuropathic pain, atypical odontalgia (phantom tooth pain), burning mouth syndrome, complex regional pain syndrome, repetitive strain injury, drug-induced peripheral neuropathy and peripheral neuropathy associated with infection.

### Claim 29 (depends on 21, 22, 23, 24, 25, 26, 27, 28)

Use of any one of claims 21 to 28, wherein the peptide is formulated for administration sequentially, or in combination, with a second agent capable of alleviating pain in the subject, wherein the second agent is not the peptide of formula (I) or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 29)

Use of claim 29, wherein the second agent is capable of alleviating nociceptive pain in the subject.

### Claim 31

A pharmaceutical composition comprising:
(i) a peptide of formula (I), or a pharmaceutically acceptable salt thereof:
(I)
(SEQ ID NO: 1)
R1-CRSVEGSCG-R2
wherein
R1 is selected from the group consisting of YLRIVQ, LRIVQ, RIVQ, IVQ, VQ, and Q, or R1 is absent; and
R2 is F (phenylalanine), or R2 is absent, and
(ii) a second agent capable of alleviating pain in the subject, wherein the second agent is not the peptide of formula (or a pharmaceutically acceptable salt thereof.

### Claim 32 (depends on 31)

The composition of claim 31, wherein the peptide is selected from the group consisting of YLRIVQCRSVEGSCGF (SEQ ID NO:2), LRIVQCRSVEGSCGF (SEQ ID NO:3), CRSVEGSCG (SEQ ID NO:4) and CRSVEGSCGF (SEQ ID NO:5).

### Claim 33 (depends on 32)

The composition of claim 32, wherein the peptide is YLRIVQCRSVEGSCGF (SEQ ID NO:2).

### Claim 34 (depends on 32)

The composition of claim 32, wherein the peptide is CRSVEGSCG (SEQ ID NO:4).

### Claim 35 (depends on 32)

The composition of claim 32, wherein the peptide is CRSVEGSCGF (SEQ ID NO:5).

### Claim 36 (depends on 31, 32, 33, 34, 35)

The composition of any one of claims 31 to 35, wherein the second agent is capable of alleviating nociceptive pain in the subject.

### Claim 37

An analgesic composition comprising a peptide of formula (I), or a pharmaceutically acceptable salt thereof:
(I)
(SEQ ID NO: 1)
R1-CRSVEGSCG-R2
wherein
R1 is selected from the group consisting of YLRIVQ, LRIVQ, RIVQ, IVQ, VQ, and Q, or R1 is absent; and
R2 is F (phenylalanine), or R2 is absent.

### Claim 38 (depends on 37)

The composition of claim 37, wherein the peptide is selected from the group consisting of YLRIVQCRSVEGSCGF (SEQ ID NO:2), LRIVQCRSVEGSCGF (SEQ ID NO:3), CRSVEGSCG (SEQ ID NO:4) and CRSVEGSCGF (SEQ ID NO:5).

### Claim 39 (depends on 38)

The composition of claim 38, wherein the peptide is YLRIVQCRSVEGSCGF (SEQ ID NO:2).

### Claim 40 (depends on 38)

The composition of claim 38, wherein the peptide is CRSVEGSCG (SEQ ID NO:4).

### Claim 41 (depends on 38)

The composition of claim 38, wherein the peptide is CRSVEGSCGF (SEQ ID NO:5).

### Claim 42 (depends on 37, 38, 39, 40, 41)

The composition of any one of claims 37 to 41, further comprising a second agent capable of alleviating pain in the subject, wherein the second agent is not the peptide of formula (I) or a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 42)

The composition of claim 42, wherein the second agent is capable of alleviating nociceptive pain in the subject.

### Claim 44

A composition comprising a therapeutically effective amount of a peptide, or a pharmaceutically acceptable salt thereof, wherein the peptide consists of amino acid sequence CRSVEGSCG (SEQ ID NO:4) or amino acid sequence CRSVEGSCGF (SEQ ID NO:5).

### Claim 45 (depends on 44)

The composition of claim 44, further comprising a pharmaceutically acceptable carrier, excipient or diluent.

### Claim 46 (depends on 44, 45)

The composition of claim 44 or claim 45, formulated for oral administration.

### Claim 47 (depends on 44, 45, 46)

A method of treating a condition in a subject, the method comprising administering to a subject a therapeutically effective amount of the composition of any one of claims 44 to 46, wherein the condition is selected from the group consisting of sarcopenia, impaired glucose tolerance, diabetes, obesity, metabolic disease and obesity-related conditions, neuropathic pain, osteoarthritis, a disorder of muscle, a wasting disorder, cachexia, anorexia, AIDS wasting syndrome, muscular dystrophy, neuromuscular disease, motor neuron disease, diseases of the neuromuscular junction, inflammatory myopathy, a burn, injury or trauma, a condition associated with elevated LDL cholesterol, a condition associated with impaired chondrocyte, proteoglycan or collagen production or quality, a condition associated with impaired cartilage tissue formation or quality, a condition associated with impaired muscle, ligament or tendon mass, form or function, a condition associated with inflammation, trauma or a genetic abnormality affecting muscle or connective tissue, and a bone disorder.

### Claim 48

A composition comprising a peptide of SEQ ID NO: 4 or SEQ ID NO:5, or a pharmaceutically acceptable salt thereof, for use as a medicament.

### Claim 49

A method of treating neuropathic pain in a subject, the method comprising administering to a subject a therapeutically effective amount of a peptide of formula (II), or a pharmaceutically acceptable salt thereof:
(II)
(SEQ ID NO: 6)
R1-CRRFVESSC-R2
wherein
R1 is selected from the group consisting of YLRVMK, LRVMK, RVMK, VMK, MK, and K, or R1 is absent; and
R2 is selected from the group consisting of A (alanine) and AF (alanine-phenylalanine), or R2 is absent.

### Claim 50 (depends on 49)

The method of claim 49, wherein the peptide is selected from the group consisting of YLRVMKCRRFVESSCAF (SEQ ID NO:7), LRVMKCRRFVESSCAF (SEQ ID NO:8), CRRFVESSCAF (SEQ ID NO:9) and CRRFVESSCA (SEQ ID NO:10).

### Claim 51 (depends on 50)

The method of claim 50, wherein the peptide is YLRVMKCRRFVESSCAF (SEQ ID NO:7).

### Claim 52 (depends on 50)

The method of claim 50, wherein the peptide is CRRFVESSCAF (SEQ ID NO:9).

### Claim 53 (depends on 50)

The method of claim 50, wherein the peptide is CRRFVESSCA (SEQ ID NO:10).

### Claim 54 (depends on 49, 50, 51, 52, 53)

The method of any one of claims 49 to 53, wherein said therapeutically effective amount alleviates neuropathic pain in the subject in the absence of a therapeutically effective analgesic effect on nociceptive pain.

### Claim 55 (depends on 49, 50, 51, 52, 53, 54)

The method of any one of claims 49 to 54, wherein the subject is selected from the group consisting of a feline, a canine and an equine.

### Claim 56 (depends on 49, 50, 51, 52, 53, 54, 55)

The method of any one of claims 49 to 55, further comprising administering to the subject a therapeutically effective amount of a second agent capable of alleviating pain in the subject, wherein the second agent is not the peptide of formula (II) or a pharmaceutically acceptable salt thereof.

### Claim 57 (depends on 56)

The method of claim 56, wherein the second agent is capable of alleviating nociceptive pain in the subject.

### Claim 58

A pharmaceutical composition comprising a peptide of formula (II), or a pharmaceutically acceptable salt thereof, for use in the treatment of neuropathic pain in a subject:
(II)
(SEQ ID NO: 6)
R1-CRRFVESSC-R2
wherein
R1 is selected from the group consisting of YLRVMK, LRVMK, RVMK, VMK, MK, and K, or R1 is absent; and
R2 is selected from the group consisting of A (alanine) and AF (alanine-phenylalanine), or R2 is absent.

### Claim 59 (depends on 58)

The composition for use according to claim 58, wherein the peptide is selected from the group consisting of YLRVMKCRRFVESSCAF (SEQ ID NO:7), LRVMKCRRFVESSCAF (SEQ ID NO:8), CRRFVESSCAF (SEQ ID NO:9) and CRRFVESSCA (SEQ ID NO:10).

### Claim 60 (depends on 59)

The composition for use according to claim 59, wherein the peptide is YLRVMKCRRFVESSCAF (SEQ ID NO:7).

### Claim 61 (depends on 59)

The composition for use according to claim 59, wherein the peptide is CRRFVESSCAF (SEQ ID NO:9).

### Claim 62 (depends on 59)

The composition for use according to claim 59, wherein the peptide is CRRFVESSCA (SEQ ID NO:10).

### Claim 63 (depends on 58, 59, 60, 61, 62)

The composition for use according to any one of claims 58 to 62, wherein the peptide, or the pharmaceutically acceptable salt thereof, is present in a therapeutically effective amount that, when administered to a subject, alleviates neuropathic pain in the subject in the absence of a therapeutically effective analgesic effect on nociceptive pain.

### Claim 64 (depends on 58, 59, 60, 61, 62, 63)

The composition for use according to any one of claims 58 to 63, wherein the subject is selected from the group consisting of a feline, a canine and an equine.

### Claim 65 (depends on 58, 59, 60, 61, 62, 63, 64)

The composition for use according to any one of claims 58 to 64, further comprising a second agent capable of alleviating pain in the subject, wherein the second agent is not the peptide of formula (II) or a pharmaceutically acceptable salt thereof.

### Claim 66 (depends on 65)

The composition for use according to claim 65, wherein the second agent is capable of alleviating nociceptive pain in the subject.

### Claim 67

A composition comprising a peptide of SEQ ID NO: 9 or SEQ ID NO:10, or a pharmaceutically acceptable salt thereof, for use as a medicament.

### Claim 68

Use of a peptide of formula (II), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of neuropathic pain in a subject:
(II)
(SEQ ID NO: 6)
R1-CRRFVESSC-R2
wherein
R1 is selected from the group consisting of YLRVMK, LRVMK, RVMK, VMK, MK, and K, or R1 is absent; and
R2 is selected from the group consisting of A (alanine) and AF (alanine-phenylalanine), or R2 is absent.

### Claim 69 (depends on 68)

Use of claim 68, wherein the peptide is selected from the group consisting of YLRVMKCRRFVESSCAF (SEQ ID NO:7), LRVMKCRRFVESSCAF (SEQ ID NO:8), CRRFVESSCAF (SEQ ID NO:9) and CRRFVESSCA (SEQ ID NO:10).

### Claim 70 (depends on 69)

Use of claim 69, wherein the peptide is YLRVMKCRRFVESSCAF (SEQ ID NO:7).

### Claim 71 (depends on 69)

Use of claim 69, wherein the peptide is CRRFVESSCAF (SEQ ID NO:9).

### Claim 72 (depends on 69)

Use of claim 69, wherein the peptide is CRRFVESSCA (SEQ ID NO:10).

### Claim 73 (depends on 68, 69, 70, 71, 72)

Use of any one of claims 68 to 72, wherein the peptide, or the pharmaceutically acceptable salt thereof, is formulated for administration to the subject in a therapeutically effective amount that alleviates neuropathic pain in the subject in the absence of a therapeutically effective analgesic effect on nociceptive pain.

### Claim 74 (depends on 68, 69, 70, 71, 72, 73)

Use of any one of claims 68 to 73, wherein the subject is selected from the group consisting of a feline, a canine and an equine.

### Claim 75 (depends on 68, 69, 70, 71, 72, 73, 74)

Use of any one of claims 68 to 74, wherein the peptide is formulated for administration sequentially, or in combination, with a second agent capable of alleviating pain in the subject, wherein the second agent is not the peptide of formula (II) or a pharmaceutically acceptable salt thereof.

### Claim 76 (depends on 75)

Use of claim 75, wherein the second agent is capable of alleviating nociceptive pain in the subject.

### Claim 77

A pharmaceutical composition comprising:
(i) a peptide of formula (II), or a pharmaceutically acceptable salt thereof:
(II)
(SEQ ID NO: 6)
R1-CRRFVESSC-R2
wherein
R1 is selected from the group consisting of YLRVMK, LRVMK, RVMK, VMK, MK, and K, or R1 is absent; and
R2 is selected from the group consisting of A (alanine) and AF (alanine-phenylalanine), or R2 is absent, and
(ii) a second agent capable of alleviating pain in the subject, wherein the second agent is not the peptide of formula (II) or a pharmaceutically acceptable salt thereof.

### Claim 78 (depends on 77)

The composition of claim 77, wherein the peptide is selected from the group consisting of YLRVMKCRRFVESSCAF (SEQ ID NO:7), LRVMKCRRFVESSCAF (SEQ ID NO:8), CRRFVESSCAF (SEQ ID NO:9) and CRRFVESSCA (SEQ ID NO:10).

### Claim 79 (depends on 78)

The composition of claim 78, wherein the peptide is YLRVMKCRRFVESSCAF (SEQ ID NO:7).

### Claim 80 (depends on 78)

The composition of claim 78, wherein the peptide is CRRFVESSCAF (SEQ ID NO:9).

### Claim 81 (depends on 78)

The composition of claim 78, wherein the peptide is CRRFVESSCA (SEQ ID NO:10).

### Claim 82 (depends on 77, 78, 79, 80, 81)

The composition of any one of claims 77 to 81, wherein the second agent is capable of alleviating nociceptive pain in the subject.

### Claim 83

An analgesic composition comprising a peptide of formula (II), or a pharmaceutically acceptable salt thereof:
(II)
(SEQ ID NO: 6)
R1-CRRFVESSC-R2
wherein
R1 is selected from the group consisting of YLRVMK, LRVMK, RVMK, VMK, MK, and K, or R1 is absent; and
R2 is selected from the group consisting of A (alanine) and AF (alanine-phenylalanine), or R2 is absent.

### Claim 84 (depends on 83)

The composition of claim 83, wherein the peptide is selected from the group consisting of YLRVMKCRRFVESSCAF (SEQ ID NO:7), LRVMKCRRFVESSCAF (SEQ ID NO:8), CRRFVESSCAF (SEQ ID NO:9) and CRRFVESSCA (SEQ ID NO:10).

### Claim 85 (depends on 84)

The composition of claim 84, wherein the peptide is YLRVMKCRRFVESSCAF (SEQ ID NO:7).

### Claim 86 (depends on 84)

The composition of claim 84, wherein the peptide is CRRFVESSCAF (SEQ ID NO:9).

### Claim 87 (depends on 84)

The composition of claim 84, wherein the peptide is CRRFVESSCA (SEQ ID NO:10).

### Claim 88 (depends on 83, 84, 85, 86, 87)

The composition of any one of claims 83 to 87, further comprising a second agent capable of alleviating pain in the subject, wherein the second agent is not the peptide of formula (II) or a pharmaceutically acceptable salt thereof.

### Claim 89 (depends on 88)

The composition of claim 88, wherein the second agent is capable of alleviating nociceptive pain in the subject.

### Claim 90

A method of treating a condition in a subject, the method comprising administering to a subject a therapeutically effective amount of a composition comprising a peptide of formula (II), or a pharmaceutically acceptable salt thereof:
(II)
(SEQ ID NO: 6)
R1-CRRFVESSC-R2
wherein
R1 is selected from the group consisting of YLRVMK, LRVMK, RVMK, VMK, MK, and K, or R1 is absent; and
R2 is selected from the group consisting of A (alanine) and AF (alanine-phenylalanine), or R2 is absent, and
wherein the condition is selected from the group consisting of sarcopenia, impaired glucose tolerance, diabetes, obesity, metabolic disease and obesity-related conditions, neuropathic pain, osteoarthritis, a disorder of muscle, a wasting disorder, cachexia, anorexia, AIDS wasting syndrome, muscular dystrophy, neuromuscular disease, motor neuron disease, diseases of the neuromuscular junction, inflammatory myopathy, a burn, injury or trauma, a condition associated with elevated LDL cholesterol, a condition associated with impaired chondrocyte, proteoglycan or collagen production or quality, a condition associated with impaired cartilage tissue formation or quality, a condition associated with impaired muscle, ligament or tendon mass, form or function, a condition associated with inflammation, trauma or a genetic abnormality affecting muscle or connective tissue, and a bone disorder.
